Rituximab-induced direct inhibition of T-cell activation |
| |
Authors: | Dina Stroopinsky Tamar Katz Jacob M Rowe Doron Melamed Irit Avivi |
| |
Institution: | Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel. |
| |
Abstract: | Background Rituximab, an anti-CD20 monoclonal antibody, is reported to increase the T-cell-dependent infection risk. The current study was designed to investigate whether rituximab interferes with T-cell activation. Patients and methods Patients with non-Hodgkin lymphoma receiving 4–6 courses of 375?mg/m2 rituximab underwent detailed assessment of T-cell activation pre- and post-rituximab. A similar analysis assessed the in vitro effect of rituximab on T-cell activation in response to allogeneic dendritic cells (allo-DCs) and other stimuli. Results Patients receiving rituximab exhibited a significant decline in IL-2 and IFN-γ levels in peripheral blood, most prominent after repeated rituximab courses. Evaluation at 3?months after rituximab therapy showed restoration of inflammatory cytokine production. Similarly, in vitro stimulation of peripheral blood mononuclear cells in the presence of rituximab resulted in a significant decrease in T-cell activation markers, inflammatory cytokine production and proliferative capacity. These effects were also observed using B-cell-depleted T cells (CD3+CD25?CD19?) and were accompanied with disappearance of CD3+CD20dim T-cell population. Conclusion Rituximab administration results in transient, dose-dependent T-cell inactivation. This effect is obtained even in B-cell absence and may increase the infection risk. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|